Immunic (IMUX) Shares Outstanding (Weighted Average) (2013 - 2026)

Immunic has disclosed Shares Outstanding (Weighted Average) across 14 years of filings, most recently posting $30.1 million for Q1 2026.

• Shares Outstanding (Weighted Average) for Q1 2026 came in at $30.1 million, up 197.37% year-over-year; the trailing twelve-month figure through Mar 2026 was $30.1 million (up 197.37% YoY), and the FY2025 annual result was $155.7 million, up 55.42% from the prior year.
• Shares Outstanding (Weighted Average) came in at $30.1 million for Q1 2026 at Immunic, down from $155.7 million in the prior quarter.
• In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $155.7 million in Q4 2025 to a low of $8.6 million in Q2 2025.
• The 5-year median for Shares Outstanding (Weighted Average) is $44.3 million (2023), against an average of $61.3 million.
• Across the five-year window, Shares Outstanding (Weighted Average) plunged 91.53% in 2025 and jumped 197.37% in 2026, its largest moves.
• Immunic's Shares Outstanding (Weighted Average) stood at $31.8 million in 2022, then surged by 39.29% to $44.3 million in 2023, then soared by 126.03% to $100.2 million in 2024, then soared by 55.42% to $155.7 million in 2025, then slumped by 80.64% to $30.1 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $30.1 million (Q1 2026), $155.7 million (Q4 2025), and $142.8 million (Q3 2025), per Business Quant data.